Answers are grounded in this paper and cite their sources.
Soon after publications initially describe the actions of new drugs with high maximum effects but low therapeutic indexes, toxic reactions, often undetected in early studies, may appear.1 Ticrynafen, cimetidine, and amrinone are cases in point.Why do certain drugs produce toxicity in one of 100 patients, whereas other drugs adversely affect only one in 10,000 or 100,000 patients? Why are some patients sensitive and others resistant to a particular form of drug toxicity? Are apparent differences in toxicity among different drugs or different populations given the same drug real, or are they artifacts of ascertainment and reporting? Why are severe . . .
No takes yet. Share an insight, caveat, or question.
Elliot S. Vesell (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: